| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1038/TPJ.2016.78 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/tpj.2016.78 |
| P932 | PMC publication ID | 5380847 |
| P698 | PubMed publication ID | 27779243 |
| P50 | author | Daniel Shriner | Q56456791 |
| P2093 | author name string | J L Baker | |
| A R Bentley | |||
| C N Rotimi | |||
| P2860 | cites work | Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals | Q59297255 |
| Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine | Q73257115 | ||
| Molecular subtypes of the HLA-DR antigens in pulmonary tuberculosis | Q73443526 | ||
| Global patterns of genetic diversity and signals of natural selection for human ADME genes | Q82474547 | ||
| Evidence that two main bottleneck events shaped modern human genetic diversity | Q84664379 | ||
| Differences between Trypanosoma brucei gambiense groups 1 and 2 in their resistance to killing by trypanolytic factor 1 | Q21092282 | ||
| A long neglected world malaria map: Plasmodium vivax endemicity in 2010 | Q21144495 | ||
| The geographic spread of the CCR5 Delta32 HIV-resistance allele | Q21146086 | ||
| The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide | Q21563408 | ||
| Use of chemokine receptors by poxviruses | Q22010876 | ||
| The genetic structure and history of Africans and African Americans | Q22065887 | ||
| Evaluating plague and smallpox as historical selective pressures for the CCR5-Delta 32 HIV-resistance allele | Q22066229 | ||
| Potential etiologic and functional implications of genome-wide association loci for human diseases and traits | Q22066284 | ||
| The Resistance Factor to Plasmodium vivax in Blacks | Q22250916 | ||
| Current findings, challenges and novel approaches in human genetic susceptibility to tuberculosis | Q22251435 | ||
| Genome-wide detection and characterization of positive selection in human populations | Q23000444 | ||
| Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 | ||
| Cloning and functional expression of a human liver organic cation transporter | Q24310500 | ||
| Cloning and characterization of two human polyspecific organic cation transporters | Q24323328 | ||
| Genetic diversity among Lassa virus strains | Q24525321 | ||
| Support from the relationship of genetic and geographic distance in human populations for a serial founder effect originating in Africa | Q24536807 | ||
| Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes | Q24538942 | ||
| Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people | Q24600330 | ||
| Association of trypanolytic ApoL1 variants with kidney disease in African Americans | Q24606581 | ||
| The global distribution of the Duffy blood group | Q24620738 | ||
| APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy | Q24631837 | ||
| CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network | Q24632735 | ||
| Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis | Q24633916 | ||
| Protection afforded by sickle-cell trait against subtertian malareal infection | Q24671995 | ||
| Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1 | Q24675093 | ||
| A global reference for human genetic variation | Q25909434 | ||
| Pharmacogenetics as a tool to tailor antiretroviral therapy: A review | Q26797938 | ||
| Investigating the Pathogenesis of Severe Malaria: A Multidisciplinary and Cross-Geographical Approach | Q26799717 | ||
| Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance | Q26864290 | ||
| Mapping the zoonotic niche of Lassa fever in Africa | Q27001682 | ||
| Twenty years post-NIH Revitalization Act: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual... | Q27023862 | ||
| Epidemiology of human African trypanosomiasis | Q27026504 | ||
| Genetic variations in HLA-B region and hypersensitivity reactions to abacavir | Q28214097 | ||
| Protective effects of the sickle cell gene against malaria morbidity and mortality | Q28215309 | ||
| Genetic structure of human populations | Q28218564 | ||
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
| Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study | Q28269827 | ||
| Common west African HLA antigens are associated with protection from severe malaria | Q28288693 | ||
| Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation | Q28290595 | ||
| Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus | Q28291275 | ||
| Siglecs and their roles in the immune system | Q28294469 | ||
| G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map | Q28485156 | ||
| Discovery of Infection Associated Metabolic Markers in Human African Trypanosomiasis | Q28550504 | ||
| Distribution of the HIV resistance CCR5-Delta32 allele among Egyptians and Syrians | Q39424652 | ||
| The first case of Lassa fever imported from Mali to the United Kingdom, February 2009. | Q40393878 | ||
| Clinical, epidemiologic, and therapeutic aspects of Lassa fever | Q40811789 | ||
| Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone | Q40903379 | ||
| Cellular mechanism for the protective effect of haemoglobin S against P. falciparum malaria | Q40913951 | ||
| Lassa fever, a new virus disease of man from West Africa. 3. Isolation and characterization of the virus | Q40932147 | ||
| Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study | Q41377430 | ||
| Pharmacometrics: opportunity for reducing disease burden in the developing world: the case of Africa | Q42249532 | ||
| Population genetics of IFIH1: ancient population structure, local selection, and implications for susceptibility to type 1 diabetes | Q43031184 | ||
| The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. | Q43521980 | ||
| Genotype and allele frequency of a 32-base pair deletion mutation in the CCR5 gene in various ethnic groups: absence of mutation among Asians and Pacific Islanders | Q43570037 | ||
| G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests | Q43721671 | ||
| Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate | Q43863009 | ||
| Natural resistance to HIV? | Q43910982 | ||
| Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa | Q43932822 | ||
| Distribution of HLA-A, B and DRB1 alleles in Sahariya tribe of North Central India: an association with pulmonary tuberculosis | Q44000756 | ||
| Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients | Q44281312 | ||
| The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity | Q44391267 | ||
| Consistency of genome-wide associations across major ancestral groups | Q44515366 | ||
| High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe | Q46526697 | ||
| Natural selection and resistance to HIV. | Q46753804 | ||
| Absence of APOL1 risk variants protects against HIV-associated nephropathy in the Ethiopian population | Q46897462 | ||
| Glucose-6-phosphate dehydrogenase and malaria. Greater resistance of females heterozygous for enzyme deficiency and of males with non-deficient variant | Q46973697 | ||
| Increased susceptibility of Fas ligand-deficient gld mice to Trypanosoma cruzi infection due to a Th2-biased host immune response. | Q52908239 | ||
| Fas-FasL interaction modulates nitric oxide production in Trypanosoma cruzi-infected mice. | Q52931841 | ||
| High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study | Q56829831 | ||
| Pharmacogenomics, ancestry and clinical decision making for global populations | Q57278395 | ||
| Ethnic Diversity and Its Environmental Determinants: Effects of Climate, Pathogens, and Habitat Diversity | Q57539943 | ||
| Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles | Q58003139 | ||
| Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee | Q58842952 | ||
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | Q34117815 | ||
| Sleeping sickness: a tale of two diseases. | Q34118109 | ||
| Posttranslational modification of alpha-dystroglycan, the cellular receptor for arenaviruses, by the glycosyltransferase LARGE is critical for virus binding. | Q34123911 | ||
| CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants | Q34125166 | ||
| Ancestry and disease in the age of genomic medicine | Q34143193 | ||
| Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings | Q34204840 | ||
| Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence | Q34213787 | ||
| Mechanism of Trypanosoma brucei gambiense resistance to human serum | Q34365663 | ||
| APOL1 risk variants, race, and progression of chronic kidney disease | Q34383679 | ||
| Global distribution of the CCR5 gene 32-basepair deletion. | Q34425080 | ||
| The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. | Q34456594 | ||
| Plasmodium vivax infection among Duffy antigen-negative individuals from the Brazilian Amazon region: an exception? | Q34644273 | ||
| Lassa fever. Effective therapy with ribavirin | Q34694588 | ||
| Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic | Q34733732 | ||
| A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis | Q34733739 | ||
| Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study | Q34756398 | ||
| Clinical and pharmacogenomic implications of genetic variation in a Southern Ethiopian population | Q34778035 | ||
| Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations | Q34826590 | ||
| The African Genome Variation Project shapes medical genetics in Africa | Q34979569 | ||
| Generalization and dilution of association results from European GWAS in populations of non-European ancestry: the PAGE study | Q34998144 | ||
| Next generation disparities in human genomics: concerns and remedies | Q35008340 | ||
| Genomic and personalized medicine: foundations and applications | Q35014059 | ||
| Genetic susceptibility to tuberculosis in Africans: a genome-wide scan | Q35174396 | ||
| The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. | Q35191432 | ||
| The clinical role and cost-effectiveness of long-acting antiretroviral therapy | Q35197271 | ||
| Genetic variation and pharmacogenomics: concepts, facts, and challenges | Q35236771 | ||
| Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences | Q35238375 | ||
| Moving toward true inclusion of racial/ethnic minorities in federally funded studies. A key step for achieving respiratory health equality in the United States. | Q35261972 | ||
| Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study | Q35426496 | ||
| Genetic analysis implicates resistin in HIV lipodystrophy | Q35538933 | ||
| Patterns of ethnic diversity among the genes that influence AIDS. | Q35649567 | ||
| Updated estimate of the duration of the meningo-encephalitic stage in gambiense human African trypanosomiasis | Q35682276 | ||
| Genome-wide scans provide evidence for positive selection of genes implicated in Lassa fever | Q35701103 | ||
| Plasmodium vivax Transmission in Africa | Q35847037 | ||
| Diversity in Clinical and Biomedical Research: A Promise Yet to Be Fulfilled | Q35869663 | ||
| Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices | Q35872678 | ||
| Association between human leukocyte antigen class II and pulmonary tuberculosis due to mycobacterium tuberculosis in Uganda | Q35902458 | ||
| Distribution of human CYP2C8*2 allele in three different African populations | Q35963368 | ||
| Low prevalence of CCR5-Δ32, CCR2-64I and SDF1-3'A alleles in the Baiga and Gond tribes of Central India. | Q35991885 | ||
| Human African trypanosomiasis: clinical presentation and immune response | Q36072554 | ||
| Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients | Q36074119 | ||
| APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans | Q36223249 | ||
| Evaluation of genome wide association study associated type 2 diabetes susceptibility loci in sub Saharan Africans | Q36309642 | ||
| Differential evolution of a CXCR4-using HIV-1 strain in CCR5wt/wt and CCR5∆32/∆32 hosts revealed by longitudinal deep sequencing and phylogenetic reconstruction. | Q36343848 | ||
| HLA class II disease associations in southern Africa | Q36379492 | ||
| The future of genomic medicine education in Africa | Q28645593 | ||
| Where Next for Genetics and Genomics? | Q28645977 | ||
| The H3Africa policy framework: negotiating fairness in genomics | Q28648286 | ||
| What does genomic medicine mean for diverse populations? | Q28659678 | ||
| Ethiopian genetic diversity reveals linguistic stratification and complex influences on the Ethiopian gene pool | Q28729180 | ||
| Trends in population-based studies of human genetics in infectious diseases | Q28732216 | ||
| Genome-wide identification of susceptibility alleles for viral infections through a population genetics approach | Q28748816 | ||
| African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping | Q28748891 | ||
| The evolution of human genetic and phenotypic variation in Africa | Q28749146 | ||
| Estimates of the duration of the early and late stage of gambiense sleeping sickness | Q28755434 | ||
| Worldwide human relationships inferred from genome-wide patterns of variation | Q29547228 | ||
| Haplotype diversity and linkage disequilibrium at human G6PD: recent origin of alleles that confer malarial resistance | Q29614684 | ||
| Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene | Q29614892 | ||
| IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy | Q29614896 | ||
| Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection | Q29614956 | ||
| The neglected burden of Plasmodium vivax malaria | Q29618450 | ||
| Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C | Q29619541 | ||
| Detection of the CCR5-Delta32 HIV resistance gene in Bronze Age skeletons. | Q30350498 | ||
| Global epidemiology of HIV. | Q30353968 | ||
| Risk maps of Lassa fever in West Africa | Q33414102 | ||
| Association of HLA-A, -B, and -DRB1 with pulmonary tuberculosis in western Javanese Indonesia | Q33571165 | ||
| Evolution of the primate trypanolytic factor APOL1 | Q33665446 | ||
| Trypanosomiasis-induced Th17-like immune responses in carp. | Q33707467 | ||
| Genetic variants associated with complex human diseases show wide variation across multiple populations | Q33714507 | ||
| Bayesian geostatistical analysis and prediction of Rhodesian human African trypanosomiasis | Q33784178 | ||
| The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: the way forward | Q33834072 | ||
| Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes | Q33876727 | ||
| Enzymatic deficiency in primaquine-sensitive erythrocytes | Q33969317 | ||
| Pharmacogenetics of antimalarial drugs: effect on metabolism and transport | Q34020238 | ||
| Can pharmacogenomics improve malaria drug policy? | Q34029396 | ||
| Type 2 diabetes risk alleles demonstrate extreme directional differentiation among human populations, compared to other diseases | Q34031536 | ||
| Genome-wide genotype and sequence-based reconstruction of the 140,000 year history of modern human ancestry | Q34038606 | ||
| Duration of symptoms and case fatality of sleeping sickness caused by Trypanosoma brucei rhodesiense in Tororo, Uganda | Q34066335 | ||
| Research capacity. Enabling the genomic revolution in Africa | Q34068017 | ||
| Signatures of environmental genetic adaptation pinpoint pathogens as the main selective pressure through human evolution | Q34071411 | ||
| Genetic perspectives on human origins and differentiation | Q34101048 | ||
| PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients | Q36468872 | ||
| APOL1 Genotype, Kidney and Cardiovascular Disease, and Death in Older Adults | Q36520457 | ||
| Human leukocyte antigens and susceptibility to tuberculosis: a meta-analysis of case-control studies. | Q36539390 | ||
| Antituberculosis drugs and hepatotoxicity | Q36628708 | ||
| Duffy blood group and malaria | Q36868609 | ||
| Drug-resistant malaria - an insight | Q36933785 | ||
| Challenges in human genetic diversity: demographic history and adaptation | Q36958118 | ||
| Antituberculosis drug-induced hepatotoxicity: concise up-to-date review | Q36998032 | ||
| Identifying Darwinian selection acting on different human APOL1 variants among diverse African populations. | Q37010357 | ||
| Imported lassa fever in Germany: molecular characterization of a new lassa virus strain | Q37064973 | ||
| Widespread balancing selection and pathogen-driven selection at blood group antigen genes | Q37119639 | ||
| Artemisinin-based combination therapy for uncomplicated malaria in sub-Saharan Africa: the efficacy, safety, resistance and policy implementation since Abuja 2000. | Q37171336 | ||
| Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy | Q37278622 | ||
| Successful translation of pharmacogenetics into the clinic: the abacavir example | Q37436365 | ||
| A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans | Q37471061 | ||
| Individualized genomics and the future of translational medicine | Q37483876 | ||
| Severity of human african trypanosomiasis in East Africa is associated with geographic location, parasite genotype, and host inflammatory cytokine response profile | Q37624109 | ||
| The next-generation sequencing revolution and its impact on genomics | Q37672566 | ||
| Genomic medicine in Africa: promise, problems and prospects | Q37690919 | ||
| Increased burden of cardiovascular disease in carriers of APOL1 genetic variants | Q37696155 | ||
| End-stage renal disease in African Americans with lupus nephritis is associated with APOL1 | Q37728822 | ||
| NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis | Q37992742 | ||
| G6PD deficiency: global distribution, genetic variants and primaquine therapy | Q38079323 | ||
| Next-generation sequencing platforms | Q38096497 | ||
| African variation at Cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases. | Q38183664 | ||
| Cytochrome P450 pharmacogenetics in African populations: implications for public health | Q38192688 | ||
| The molecular arms race between African trypanosomes and humans | Q38224214 | ||
| Provision of antiretroviral therapy in South Africa: the nuts and bolts | Q38259626 | ||
| A co-evolutionary arms race: trypanosomes shaping the human genome, humans shaping the trypanosome genome | Q38345868 | ||
| Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions. | Q38622785 | ||
| Beyond Tsetse--Implications for Research and Control of Human African Trypanosomiasis Epidemics | Q38716735 | ||
| Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy | Q38870064 | ||
| Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial | Q39000745 | ||
| The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression | Q39249450 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | infection | Q166231 |
| genetics | Q7162 | ||
| genetic variation | Q349856 | ||
| molecular evolution | Q856529 | ||
| infectious disease | Q18123741 | ||
| pharmacogenomics | Q1152227 | ||
| pharmacogenetics | Q1358521 | ||
| pharmacogenomic variants | Q71227267 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 112-120 | |
| P577 | publication date | 2016-10-25 | |
| 2017-03-01 | |||
| P1433 | published in | The Pharmacogenomics Journal | Q10534704 |
| P1476 | title | Pharmacogenomic implications of the evolutionary history of infectious diseases in Africa | |
| P478 | volume | 17 |
| Q48248566 | APOL1, CDKN2A/CDKN2B, and HDAC9 Polymorphisms and Small Vessel Ischemic Stroke |
| Q60908142 | Estimated glomerular filtration rate predicts incident stroke among Ghanaians with diabetes and hypertension |
| Q90093635 | Evaluating the promise of inclusion of African ancestry populations in genomics |
| Q92886001 | Genetic analyses of diverse populations improves discovery for complex traits |
| Q92582954 | The Emergence of Genomic Research in Africa and New Frameworks for Equity in Biomedical Research |
| Q41924616 | The genomic landscape of African populations in health and disease |
| Q53688374 | Whole-Exome Sequencing Reveals Uncaptured Variation and Distinct Ancestry in the Southern African Population of Botswana. |
Search more.